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Abstract Chronic granulomatous disease (CGD) is characterized by a disability to produce
reactive oxygen intermediates (ROI) caused by a defect of phagocyte nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase. A hyperinflammatory response to immune activation has
been reported to contribute to the pathology of CGD. The tryptophan catabolizing enzyme
indoleamine 2,3-dioxygenase (IDO) is considered critical for regulating immune responses and
suppression of inflammation. IDO is generally believed to require ROI for enzymatic activity andwas
found to be inactive in murine CGD. Here, we report that, strikingly, in human CGD IDO metabolic
activity is intact. Monocyte-derived dendritic cells generated from CGD patients, harbouring X-
linked and autosomal recessive forms of CGD, and from healthy controls produced similar amounts
of the tryptophanmetabolite kynurenine upon activationwith lipopolysaccharide and interferon-γ.
Thus, in humans, ROI apparently are dispensable for IDO activity. Hyperinflammation in human CGD
cannot be attributed to disabled IDO activation.
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Chronic granulomatous disease (CGD) is an inherited immuno-
deficiency characterized by recurrent severe bacterial and
fungal infections. The underlying genetic defect of thephagocyte nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase results in failure to produce reactive oxygen
intermediates (ROI), favoring invasive infections [1]. CGD is
also characterized by a hyperinflammatory response following
immune activation [2,3], which might lead to granuloma
formation even in the absence of pathogen [4]. A recent report
proposed that impaired activation of the immunoregulatory
indoleamine 2,3-dioxygenase (IDO) pathway [5–7] contributed
to an amplified inflammatory response inmurine CGD [8]. IDO,
mediating tryptophan metabolism, is a heme-containing
enzyme and requires posttranslational activation through the
reduction of the ferric (Fe3+) to the ferrous (Fe2+) form [9]
before the metabolic breakdown of tryptophan along the
kynurenine pathway can be initiated. Previous studies





Diagnosis Clinical course Treatment
Functional Genotype
1 M, 5 years 2 years CL b 1% p91phox Clinically well Prophylactic TMP, Itra
2a M, 11 years 11 years DHR 0% p47phox Recurrent blepharitis, recurrent skin




3 a F, 8 years 8 years DHR 11% p47phox Recurrent diarrhea, recurrent oral ulcers,




4 F, 12 years 6 years DHR 0% p47phox Multifocal pleuropneumonia (Burkholderia
multivorans) at age 6 years, clinically well
at blood collection
None (non-compliant)
Abbreviations: M, male; F, female; CL, chemiluminescence; DHR, dihydrorhodamine; NBT, nitroblue tetrazolium; TMP, trimethoprim; Itra,
itraconazole.
a Siblings.
2 Rapid Communicationproposed an essential role for superoxide and ROI for IDO
activation [10,11]. In consistence with this concept, IDO
activity was found to be abolished in CGD mice [8]. CGD (p47
phox−/−) (phox, phagocytic oxidase) mice responded to
experimental Aspergillus infection with hyperinflammation,
indicated by severe lung injury and a Th17 polarized response,
and showed reversal of the hyperinflammatory phenotype upon
application of the tryptophan breakdown product kynurenine.
As this finding may have significant impact on the under-
standing of CGD pathophysiology, we investigated whether
defective IDO activation was also present in human CGD.
Methods
Heparinized blood was collected after written informed
consent from four CGD patients, including one with X-linked
(gp91phox) and three with autosomal recessive (p47phox)
inheritance (Table 1). All patients were free of infection and
presented no clinical or laboratory signs of inflammation at the
time of blood collection (not shown). The first diagnosis of CGD
wasmade in all patients by b10% oxygen radical production, as
determined by chemiluminescence, dihydrorhodamine, and/
or nitroblue tetrazolium tests in PMA-stimulated phagocytes,
followed by genetic analyses. Approval for this study was
obtained from the institutional review board of the St. Anna
Children's Hospital, Vienna, Austria. All patients and/or their
parents gave written informed consent.
Immature dendritic cells (DCs) were generated from CGD
patients and controls in parallel, as described [12], and were
activated with 50 ng lipopolysaccharide (LPS) (Calbiochem;
Escherichia coli O111:B4) and 1000 U/ml interferon-gamma
(IFN-γ) (Boehringer Ingelheim) for 48 hours. Following stimu-
lation, the DC recovery rate was analyzed by flow cytometry
using propidium-iodide staining. IDO protein expression was
determined by immunoblotting, using a monoclonal mouse
anti-human IDO antibody kindly provided by O. Takikawa
(National Institute for Longevity Sciences, National Center for
Geriatrics and Gerontology, Aichi, Japan) [12]. IDO activity
was determined measuring the release of the tryptophan
breakdown product kynurenine into cell culture supernatants
by high performance liquid chromatography [12]. The kynur-enine release by patient cells was compared to that of control
cells by calculating the mean kynurenine concentration±the
standard error of the mean (SEM) in cell culture supernatants.
Statistical analyses were performed using the Student's t-test
(paired, two-tailed). A p-value b0.05 was considered to
indicate statistical significance.
Results and discussion
To analyze whether the IDO immunoregulatory pathway was
impaired in human CGD, we compared the ability of IDO
activation in monocyte-derived DCs obtained from CGD
patients and from healthy controls. We activated immature
DCs with LPS and IFN-γ for 48 hours. This strategy recapitu-
lates to some extent inflammatory stimulation and consis-
tently results in abundant IDO activity in human cells [12].
To exclude that any difference in IDO activity in CGD
patients and controls was related to an altered sensitivity to
apoptosis in CGD patients, we first ascertained that the
recovery rate of CGD and control DCs after activation with
LPS/IFN-γwas within the same range (Fig. 1A). Likewise, upon
activation, patient and control DCs developed a similarly
mature phenotype, as assessed by flow cytometric staining for
expression of CD83, CD80, CD86, and HLA-DR [12] (not shown).
Next, immunoblotting of IDO protein expression showed that
LPS/IFN-γ activation of immature DCs induced comparable IDO
protein expression in CGD and in control DCs (Fig. 1B).
Strikingly, analyzing IDO activity, we found that abundant
tryptophan catabolismwas consistently inducible inDCs of CGD
patients. While immature DCs did not metabolize tryptophan
(Fig. 1C) [12], activation of DCs obtained from CGD patients
resulted in the release of 11.7±4.1 µMkynurenine, and thiswas
within the same range as that of control cells, which released
11.2±0.6 µM kynurenine (p=0.83) (Fig. 1C). These findings
clearly demonstrate that in humans the induction of IDO
enzymatic activity is not essentially dependent of ROI and that
the IDO activity in CGD patients is preserved.
In accordance with our findings and contrasting the
previous concept of IDO activation being dependent on super-
oxide and ROI [10], a recent study reported that in human
cells superoxide dismutase mimetics, while being able to
Figure 1 Normal expression and activation of IDO in DCs of human CGD patients. (A) Recovery rate of DCs after activationwith LPS/IFN-
γ for 48 hours as healthy control derived DCs. (B) IDO immunoblotting; note that immunoblotting of immature DCs (iDC) was not possible
due to low cell numbers obtained frompatients 2–4. (C) kynurenine release into cell culture supernatants; gray bars, immature DCs; black
bars, DCs activated with LPS/IFN-γ for 48 hours. co, control; pt, patient; KYN, kynurenine.
3Rapid Communicationdecrease intracellular superoxide, failed to significantly alter
IDO activity. Instead, cytochrome b5, in the presence of
cytochrome P450 reductase and NADPH, was found to be suf-
ficient for reduction of Fe3+-IDO to Fe2+-IDO, thus allowing for
effective initiation of IDO-mediated tryptophan breakdown
[13], indicating that cytochrome b5 rather than superoxide
plays a major role in the activation of IDO in human cells.
Yet, other ROI-dependent processes such as activation of
nuclear factor-erythroid 2-related factor 2 (Nrf2), which
serves as an antioxidant response element and restrains the
activation of NF-κB [14], might contribute to the hyperin-
flammatory state in some patients with CGD [15].
In conclusion, this study provides clear evidence that the
IDO immunoregulatory pathway is intact in humanCGD despite
defective NADPH oxidase function. Our findings are consistent
with the observation of normal kynurenine levels in the sera of
a CGD patient,who suffered from severeAspergillus infection,
before as well as after gene therapy when the patient was
cured from this infection [16]. The hyperinflammatory state in
some CGD patients may be linked to an impaired immunoreg-
ulatory activity of ROI, e.g., by insufficient Nrf2 activation, orother mechanisms still to be discovered. Should kynurenine be
considered as a treatment option in CGD at all the rationale for
its use could be to augment rather than to replace IDO-me-
diated immunoregulation.
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